Skip to main content
. 2016 Feb 21;7(13):15959–15976. doi: 10.18632/oncotarget.7557

Figure 1. In vivo pharmacodynamic activity of AZD5363 in mouse PTEN-deficient prostate tumors.

Figure 1

Twenty-week-old PTEN-KO mice (n = 3 mice per group) bearing prostate tumors were treated with AZD5363 for the indicated dosage and times. Tumors lysates were pooled and were examined by western blot for the expression of proteins and/or phosphorylation of AKT and its downstream targets A., markers of proliferation and apoptosis B., and markers of the MAPK and JAK/STAT3 signaling pathway C. Gel densitometry was quantified with ImageJ.